Protein-misfolding diseases and the paradigm of proteomics-based therapeutic targets

Expert Review of Proteomics

Volumn 7, Issue 4, 2010, Pages 463-464

  Singh, Om V ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

drug development; protein misfolding diseases; proteomics; therapeutic targets

Indexed keywords

PROTEASOME; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; EDITORIAL; GENETIC VARIABILITY; HUMAN; PARKINSON DISEASE; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN PROCESSING; PROTEOMICS; RNA TRANSCRIPTION; RNA TRANSLATION;

DRUG DELIVERY SYSTEMS; HUMANS; PROTEOMICS; PROTEOSTASIS DEFICIENCIES;

EID: 77954979768     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.71     Document Type: Editorial

References (5)

1. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899 (2003).
2. Tyers M, Mann M. From genomics to proteomics. Nature 422, 193-197 (2003).
3. Choudhary C, Mann M. Decoding signaling networks by mass spectrometry-based proteomics. Nat. Rev. Mol. Cell Biol. 11, 427-439 (2010).
4. Ng APP, Nin DS, Fong JH, Venkataraman D, Chen C-S, Khan M. Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein. Mol. Cancer Ther. 6, 2240-2248 (2007).
5. Lubin DJ, Butler JS, Loh SN. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function. J. Mol. Biol. 395, 705-716 (2010).